Indeed, in the TCGA cohort, the tumor G2M score was higher in triple negative breast cancer (TNBC) and HER2-positive subtypes (p < 0.001), which are both known to be more aggressive than ER-positive/HER2-negative subtype (Figure 2A; p < 0.001). The gene discussed is ERBB2; the disease is neoplasm.